MARKET

VSTM

VSTM

Verastem
NASDAQ
5.81
+0.21
+3.75%
After Hours: 5.82 +0.01 +0.17% 18:57 03/16 EDT
OPEN
5.61
PREV CLOSE
5.60
HIGH
5.85
LOW
5.48
VOLUME
4.23M
TURNOVER
--
52 WEEK HIGH
11.25
52 WEEK LOW
4.010
MARKET CAP
510.32M
P/E (TTM)
-1.9224
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VSTM last week (0309-0313)?
Weekly Report · 19h ago
Verastem Coverage Assumed by BTIG at Buy
Dow Jones · 4d ago
Verastem Price Target Announced at $19.00/Share by BTIG
Dow Jones · 4d ago
BTIG Assumes Verastem at Buy, Announces Price Target of $19
Benzinga · 4d ago
Verastem assumed with a Buy at BTIG
TipRanks · 5d ago
Undervalued Growth Story in Verastem: Strong AVMAPKI FAKZYNJA Launch and Promising KRASG12D Pipeline Drive Buy Rating and $19 Target
TipRanks · 5d ago
Verastem Earnings Call: Early Momentum, Long Runway Risks
TipRanks · 03/10 00:21
Verastem: Differentiated Next‑Generation KRAS G12D Inhibitor VS‑7375 Underpins Buy Rating on Compelling Early Clinical Data
TipRanks · 03/09 10:26
More
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

Webull offers Verastem Inc stock information, including NASDAQ: VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.